Aerami Therapeutics Goes Public Through SPAC Merger

Aerami Therapeutics Goes Public Through SPAC Merger

314263

Aerami Therapeutics Goes Public Through SPAC Merger

Aerami Therapeutics, a biopharmaceutical company focused on developing inhaled therapies for severe respiratory diseases — including pulmonary arterial hypertension (PAH) — has entered into a merger agreement with FoxWayne Enterprises Acquisition, a special purpose acquisition company (SPAC). The goal of this merger is to accelerate the development of Aerami’s therapeutic pipeline. SPACs, also known as “blank check companies,” are essentially shell companies with no commercial operations that are set up by investors with the purpose…

You must be logged in to read/download the full post.